StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

Investment analysts at StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Thursday. The firm set a “sell” rating on the medical technology company’s stock.

BIOLASE Trading Down 7.2 %

BIOLASE stock opened at $0.01 on Thursday. The firm has a market cap of $250,552.50, a PE ratio of 0.00 and a beta of 0.67. BIOLASE has a 12 month low of $0.02 and a 12 month high of $1.94. The stock’s 50 day simple moving average is $0.01 and its two-hundred day simple moving average is $0.02.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.